ESC 365 - ELIMINATE-AF trial in the context of other non-vitamin K antagonist oral anticoagulant trials.

EHRA Premium Access

ELIMINATE-AF trial in the context of other non-vitamin K antagonist oral anticoagulant trials.

Session: Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Topic: Oral Anticoagulation

Speaker: Professor J. Kautzner (Prague, CZ)

Sponsored by Daiichi Sankyo, Europe

Event: EHRA 2019

Congress Presentation

Add to my library

About the speaker

Professor Josef Kautzner

Institute for Clinical and Experimental Medicine (IKEM), Prague (Czechia)

41 presentations

6 followers

4 more presentations in this session

Welcome and Introduction - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Speaker: Professor S. Hohnloser (Frankfurt, DE)

Implications of non-vitamin K antagonist oral anticoagulant trials in ablation practice.

Speaker: Doctor M. Grimaldi (Acquaviva Delle Fonti, IT)

Current recommendation for atrial fibrillation patients undergoing ablation.

Speaker: Professor J. Steffel (Zurich, CH)

Panel discussion and closing remarks - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Speaker: Professor S. Hohnloser (Frankfurt, DE)

Access the full session

Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Speakers: Professor J. Kautzner, Professor S. Hohnloser, Doctor M. Grimaldi, Professor J. Steffel, Professor S. Hohnloser

About the event

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources